Genprex, Inc. Net Fee Amt
Genprex, Inc. (GNPX) had Net Fee Amt of $142.31 as of 2026-06-23, per its S-8 filed 2026-06-26.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-26
- 2026-06-23: Net Fee Amt $142.31.
- 2026-05-29: Net Fee Amt $24.01K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-23 | $142.31 S-8 · filed 2026-06-26 |
| 2026-05-29 | $24.01K S-3 · filed 2026-06-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |